drugset / Trial / NCT00546039

Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate Cancer

NCT00546039

Phase 2 Unknown 47 enrolled University Hospital, Aker
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to evaluate safety and mechanisms of possible chemopreventive effects of synthetic genistein (BONISTEIN™) in patients with localized prostate cancer undergoing laparoscopic radical prostatectomy.

Timeline

Start
2007-04
Primary completion
2008-08
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Genistein Other / unclassified 30 mg Oral

Indications